Breaking Finance News

A report released today by Citigroup about Synergy Pharma (NASDAQ:SGYP) lowers the target price to $2.50

In a report released on Wednesday September 13, 2017 Citigroup reduced the stock price target of Synergy Pharma (NASDAQ:SGYP) from $3.20 to $2.50 reporting a potential downside of -0.12%.

On 9/08/2017, Oppenheimer released a statement on Synergy Pharma (NASDAQ:SGYP) dropped the target price from $9.00 to $6.00 that suggested an upside of 0.99%.

Showing a price of $2.84, Synergy Pharma (NASDAQ:SGYP) traded -3.17% lower on the day. With the last stock price close down -33.58% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $3.31 and a 200-day moving average of $4.14. 1,158,195 shares of SGYP traded hands, down from an average trading volume of 4,439,780

Recent Performance Chart

Synergy Pharma (NASDAQ:SGYP)

Synergy Pharma has 52 week low of $2.63 and a 52 week high of $7.15 and has a market capitalization of $0.

In addition to Citigroup reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $11.30 with 2 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Synergy Pharma (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.